Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and s...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2024-04, Vol.13 (7), p.1940
Main Authors: Battista, Teresa, Gallo, Lucia, Martora, Fabrizio, Fattore, Davide, Potestio, Luca, Cacciapuoti, Sara, Scalvenzi, Massimiliano, Megna, Matteo
Format: Article
Language:English
Subjects:
Biological products
Cancer
Cancer therapies
Care and treatment
Disease
Drugs
Fungal infections
Health aspects
Immunotherapy
Lymphoma
Medical diagnosis
Melanoma
Metabolic syndrome
Patients
Psoriasis
Psoriatic arthritis
Systematic review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitant malignancy is still debated. : We have conducted a retrospective observational study of a group of oncology patients with moderate-to-severe psoriasis treated with biologic therapy at the Dermatology Clinic of the University of Naples Federico II, during the period from 2016 to 2024. We included 20 adult patients; in 15 of them the diagnosis of neoplasm preceded the start of treatment biologic, while four of these patients had been diagnosed with cancer during the course of therapy biologics. : The most represented neoplasms in our population were breast carcinoma, prostate carcinoma, thyroid carcinoma, and chronic lymphatic leukemia. Anti-IL17 drugs were the most frequently prescribed (47.7%), followed by anti-IL23p19 (36.8%), anti-IL-12/23 (10.5%) and anti-TNF alpha (5.26%). All patients showed improvement of psoriasis after starting the therapy. : Our experience supports the effectiveness and safety of biological therapy for psoriasis in patients with a history of cancer or recent onset neoplasia.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13071940